FBIO · Insider Trading
Fortress Biotech, Inc.
Every open-market purchase and sale reported by FBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | David Jin | Chief Financial Officer | A | +1,190 | +$2.16K |
| 2026-06-24 | David Jin | Chief Financial Officer | A | +400,000 | — |
| 2017-11-08 | Lindsay A Md Rosenwald | PRESIDENT, CEO | Buy | +40,000 | +$1.00M |
| 2017-07-21 | Dov Klein | Director | D | −13,333 | — |
| 2017-07-21 | Malcolm Hoenlein | Director | A | — | — |
| 2017-07-21 | Jimmie Harvey | Director | A | — | — |
| 2017-01-27 | Michael S Weiss | Exec. VC - Strategic Dev. | A | +552,698 | — |
| 2017-01-27 | Lindsay A Md Rosenwald | President and CEO | MIXED | +553,429 | +$1.48K |
| 2017-01-24 | Malcolm Hoenlein | Director | A | — | — |
| 2017-01-24 | Jimmie Harvey | Director | A | — | — |
| 2017-01-24 | Eric K Rowinsky | Director | A | +100,000 | — |
| 2017-01-24 | Dov Klein | Director | MIXED | +73,334 | — |
| 2017-01-24 | J Jay Lobell | Director | A | +100,000 | — |
| 2016-09-19 | George Avgerinos | SVP, Biologics Operations | Sell | −48,912 | −$124.58K |
| 2016-09-16 | George Avgerinos | SVP, Biologics Operations | A | +150,000 | — |
| 2016-07-19 | Dov Klein | Director | D | −13,333 | — |
| 2016-06-17 | Lindsay A Md Rosenwald | President and CEO | Buy | +613 | +$1.47K |
| 2016-03-28 | Jimmie Harvey | Director | A | — | — |
| 2016-03-28 | Malcolm Hoenlein | Director | A | — | — |
| 2016-01-05 | Michael S Weiss | Exec. VC - Strategic Dev. | A | +510,434 | — |
| 2016-01-05 | Eric K Rowinsky | Director | A | +100,000 | — |
| 2016-01-05 | Dov Klein | Director | A | +100,000 | — |
| 2016-01-05 | J Jay Lobell | Director | A | +100,000 | — |
| 2016-01-05 | Lindsay A Md Rosenwald | President and CEO | A | +510,434 | — |
| 2015-12-09 | Lindsay A Md Rosenwald | President and CEO | Buy | +586 | +$1.41K |
| 2015-09-14 | George Avgerinos | SVP, Biologics Operations | D | −54,036 | −$143.46K |
| 2015-09-10 | George Avgerinos | SVP, Biologics Operations | D | −25,804 | −$67.04K |
| 2015-09-08 | George Avgerinos | SVP, Biologics Operations | D | −2,136 | −$5.55K |
| 2015-09-04 | George Avgerinos | SVP, Biologics Operations | D | −43,100 | −$111.72K |
| 2015-09-03 | George Avgerinos | SVP, Biologics Operations | D | −158 | −$427 |
| 2015-09-02 | George Avgerinos | SVP, Biologics Operations | D | −3,500 | −$10.29K |
| 2015-08-25 | George Avgerinos | SVP, Biologics Operations | D | −10,000 | −$25.46K |
| 2015-08-21 | George Avgerinos | SVP, Biologics Operations | D | −11,266 | −$33.80K |
| 2015-08-14 | George Avgerinos | SVP, Biologics Operations | A | +300,000 | — |
| 2015-07-17 | George Avgerinos | SVP, Biologics Operations | D | — | — |
| 2015-07-17 | Dov Klein | Director | A | +50,000 | — |
| 2015-06-03 | Lindsay A Md Rosenwald | President and CEO | Buy | +785 | +$1.41K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Jin | Chief Financial Officer | 1,652,761 | $3.09M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.